Cytogen (A217330) Stock Overview
A biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
A217330 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Cytogen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩8,030.00 |
| 52 Week High | ₩11,200.00 |
| 52 Week Low | ₩2,260.00 |
| Beta | 0.00052 |
| 1 Month Change | 0.37% |
| 3 Month Change | 159.03% |
| 1 Year Change | 76.68% |
| 3 Year Change | -49.72% |
| 5 Year Change | -56.98% |
| Change since IPO | 54.42% |
Recent News & Updates
Market Might Still Lack Some Conviction On Cytogen, Inc. (KOSDAQ:217330) Even After 33% Share Price Boost
Dec 09
Cytogen (KOSDAQ:217330) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Nov 18The Market Lifts Cytogen, Inc. (KOSDAQ:217330) Shares 35% But It Can Do More
Oct 10Recent updates
Market Might Still Lack Some Conviction On Cytogen, Inc. (KOSDAQ:217330) Even After 33% Share Price Boost
Dec 09Cytogen (KOSDAQ:217330) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Nov 18The Market Lifts Cytogen, Inc. (KOSDAQ:217330) Shares 35% But It Can Do More
Oct 10Cytogen, Inc.'s (KOSDAQ:217330) Subdued P/S Might Signal An Opportunity
Jun 19Is Cytogen (KOSDAQ:217330) Weighed On By Its Debt Load?
Mar 23What You Need To Know About Cytogen, Inc.'s (KOSDAQ:217330) Investor Composition
Jan 25
Is Cytogen (KOSDAQ:217330) Using Too Much Debt?
Dec 03Shareholder Returns
| A217330 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -10.6% | -5.8% | 3.3% |
| 1Y | 76.7% | 38.7% | 89.2% |
Return vs Industry: A217330 exceeded the KR Biotechs industry which returned 38.7% over the past year.
Return vs Market: A217330 underperformed the KR Market which returned 89.2% over the past year.
Price Volatility
| A217330 volatility | |
|---|---|
| A217330 Average Weekly Movement | 17.6% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in KR Market | 12.2% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A217330's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A217330's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 50 | Byung-Hee Jeon | www.cytogenlab.com |
Cytogen, Inc., a biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea. The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immunofluorescent staining system; and cell image analyzers, which help captures immunofluorescent images of cells stained with anti-EpCAM, -CD45, and CK antibodies. The company sells its products under the Smart Biopsy brand name.
Cytogen, Inc. Fundamentals Summary
| A217330 fundamental statistics | |
|---|---|
| Market cap | ₩191.48b |
| Earnings (TTM) | -₩15.23b |
| Revenue (TTM) | ₩25.09b |
Is A217330 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A217330 income statement (TTM) | |
|---|---|
| Revenue | ₩25.09b |
| Cost of Revenue | ₩19.02b |
| Gross Profit | ₩6.08b |
| Other Expenses | ₩21.31b |
| Earnings | -₩15.23b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -660.22 |
| Gross Margin | 24.22% |
| Net Profit Margin | -60.70% |
| Debt/Equity Ratio | 35.8% |
How did A217330 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/23 08:57 |
| End of Day Share Price | 2026/01/23 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cytogen, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.